HM/
Articles/
2606004309
  • Open Access
  • Review

Advances in Clinical Applications of 1H NMR-Based Urine Metabolomics

  • Qiong Yang,   
  • Zhou Zhou,   
  • Ya-Hui Lin *

Received: 09 Sep 2025 | Revised: 08 May 2026 | Accepted: 17 Jun 2026 | Published: 03 Aug 2026

Abstract

Urinary 1H Nuclear Magnetic Resonance (NMR)-based metabolomics has emerged as a robust, non-invasive approach for profiling systemic and renal metabolic alterations. This review summarizes recent clinical applications across kidney disease, cardiometabolic disorders, cancer, immune-mediated and infectious diseases, pediatric disorders, and lifestyle or environmental exposures. We first outline methodological aspects specific to urine, including sampling strategies, osmolarity variation, normalization approaches, and spectral analysis. We then discuss disease-focused applications, emphasizing key metabolites, study designs, and diagnostic performance, and we highlight areas of concordance and inconsistency cross-studies. Shared advantages and limitations of 1H NMR-based urine metabolomics are consolidated in a dedicated section on challenges, and future directions are explored with particular attention to standardization, automation, artificial intelligence–assisted spectral interpretation, multi-omics integration, and large-scale validation. A brief comparison with mass spectrometry (MS) illustrates the complementary roles of NMR and MS in clinical metabolomics. Overall, 1H NMR-based urine metabolomics has potential as a scalable platform for non-invasive phenotyping and holds considerable promise for personalized medicine once technical and translational barriers are addressed.

Graphical Abstract

Image Viewer
Open in new tab
Download Image

References 

  • 1.

    Lee, A.; Lam, C.-W. Application of Metabolic Biomarkers in Breast Cancer: A Literature Review. Ann. Lab. Med. 2025, 45, 229–246. https://doi.org/10.3343/alm.2024.0482.

  • 2.

    Bose, K.; Speyer, C.B.; Baleja, J.D. Use of nuclear magnetic resonance spectroscopy in diagnosis of inborn errors of metabolism. Emerg. Top. Life Sci. 2021, 5, 39–48. https://doi.org/10.1042/etls20200259.

  • 3.

    Li, T.; Tynkkynen, T.; Ihanus, A.; Zhao, S.; Mäkinen, V.-P.; Ala-Korpela, M. Characteristics of Normalization Methods in Quantitative Urinary Metabolomics—Implications for Epidemiological Applications and Interpretations. Biomolecules 2022, 12, 903. https://doi.org/10.3390/biom12070903.

  • 4.

    Markley, J.L.; Brüschweiler, R.; Edison, A.S.; Eghbalnia, H.R.; Powers, R.; Raftery, D.; Wishart, D.S. The future of NMR-based metabolomics. Curr. Opin. Biotechnol. 2017, 43, 34–40. https://doi.org/10.1016/j.copbio.2016.08.001.

  • 5.

    Bouatra, S.; Aziat, F.; Mandal, R.; Guo, A.C.; Wilson, M.R.; Knox, C.; Bjorndahl, T.C.; Krishnamurthy, R.; Saleem, F.; Liu, P.; et al. The Human Urine Metabolome. PLoS ONE 2013, 8, e73076. https://doi.org/10.1371/journal.pone.0073076.

  • 6.

    Beckonert, O.; Keun, H.C.; Ebbels, T.M.D.; Bundy, J.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2, 2692–2703. https://doi.org/10.1038/nprot.2007.376.

  • 7.

    Huang, K.; Thomas, N.; Gooley, P.R.; Armstrong, C.W. Systematic Review of NMR-Based Metabolomics Practices in Human Disease Research. Metabolites 2022, 12, 963. https://doi.org/10.3390/metabo12100963.

  • 8.

    Powers, R.; Andersson, E.R.; Bayless, A.L.; Brua, R.B.; Chang, M.C.; Cheng, L.L.; Clendinen, C.S.; Cochran, D.; Copié, V.; Cort, J.R.; et al. Best practices in NMR metabolomics: Current state. TrAC Trends Anal. Chem. 2024, 171, 117478. https://doi.org/10.1016/j.trac.2023.117478.

  • 9.

    Lauridsen, M.; Hansen, S.H.; Jaroszewski, J.W.; Cornett, C. Human Urine as Test Material in 1H NMR-Based Metabonomics:  Recommendations for Sample Preparation and Storage. Anal. Chem. 2007, 79, 1181–1186. https://doi.org/10.1021/ac061354x.

  • 10.

    Sumner, L.W.; Amberg, A.; Barrett, D.; Beale, M.H.; Beger, R.; Daykin, C.A.; Fan, T.W.M.; Fiehn, O.; Goodacre, R.; Griffin, J.L.; et al. Proposed minimum reporting standards for chemical analysis. Metabolomics 2007, 3, 211–221. https://doi.org/10.1007/s11306-007-0082-2.

  • 11.

    Bruzzone, C.; Loizaga-Iriarte, A.; Sánchez-Mosquera, P.; Gil-Redondo, R.; Astobiza, I.; Diercks, T.; Cortazar, A.R.; Ugalde-Olano, A.; Schäfer, H.; Blanco, F.J.; et al. 1H NMR-Based Urine Metabolomics Reveals Signs of Enhanced Carbon and Nitrogen Recycling in Prostate Cancer. J. Proteome Res. 2020, 19, 2419–2428. https://doi.org/10.1021/acs.jproteome.0c00091.

  • 12.

    Lee, S.; Ku, J.Y.; Kang, B.J.; Kim, K.H.; Ha, H.K.; Kim, S. A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma. Metabolites 2021, 11, 591. https://doi.org/10.3390/metabo11090591.

  • 13.

    Ossoliński, K.; Ruman, T.; Copié, V.; Tripet, B.P.; Kołodziej, A.; Płaza-Altamer, A.; Ossolińska, A.; Ossoliński, T.; Nieczaj, A.; Nizioł, J. Targeted and untargeted urinary metabolic profiling of bladder cancer. J. Pharm. Biomed. Anal. 2023, 233, 115473. https://doi.org/10.1016/j.jpba.2023.115473.

  • 14.

    Bifarin, O.O.; Gaul, D.A.; Sah, S.; Arnold, R.S.; Ogan, K.; Master, V.A.; Roberts, D.L.; Bergquist, S.H.; Petros, J.A.; Edison, A.S.; et al. Urine-Based Metabolomics and Machine Learning Reveals Metabolites Associated with Renal Cell Carcinoma Stage. Cancers 2021, 13, 6253. https://doi.org/10.3390/cancers13246253.

  • 15.

    Baranovicova, E.; Vnucak, M.; Granak, K.; Kleinova, P.; Halasova, E.; Dedinska, I. Assessment of metabolites in urine in post-kidney transplant patients: Insights into allograft function and creatinine clearance. Metabolomics 2025, 21, 44. https://doi.org/10.1007/s11306-025-02246-y.

  • 16.

    Dekker, S.E.I.; Verhoeven, A.; Frey, D.; Soonawala, D.; Peters, D.J.M.; Mayboroda, O.A.; de Fijter, J.W. Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients. Am. J. Nephrol. 2022, 53, 470–480. https://doi.org/10.1159/000524851.

  • 17.

    Thongprayoon, C.; Vuckovic, I.; Vaughan, L.E.; Macura, S.; Larson, N.B.; D’Costa, M.R.; Lieske, J.C.; Rule, A.D.; Denic, A. Nuclear Magnetic Resonance Metabolomic Profiling and Urine Chemistries in Incident Kidney Stone Formers Compared with Controls. J. Am. Soc. Nephrol. 2022, 33, 2071–2086. https://doi.org/10.1681/asn.2022040416.

  • 18.

    Leenders, J.; Grootveld, M.; Percival, B.; Gibson, M.; Casanova, F.; Wilson, P.B. Benchtop Low-Frequency 60 MHz NMR Analysis of Urine: A Comparative Metabolomics Investigation. Metabolites 2020, 10, 155. https://doi.org/10.3390/metabo10040155.

  • 19.

    Bruzzone, C.; Gil-Redondo, R.; Seco, M.; Barragán, R.; de la Cruz, L.; Cannet, C.; Schäfer, H.; Fang, F.; Diercks, T.; Bizkarguenaga, M.; et al. A molecular signature for the metabolic syndrome by urine metabolomics. Cardiovasc. Diabetol. 2021, 20, 155. https://doi.org/10.1186/s12933-021-01349-9.

  • 20.

    Bletsa, E.; Filippas-Dekouan, S.; Kostara, C.; Dafopoulos, P.; Dimou, A.; Pappa, E.; Chasapi, S.; Spyroulias, G.; Koutsovasilis, A.; Bairaktari, E.; et al. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2021, 106, 1269–1283. https://doi.org/10.1210/clinem/dgab086.

  • 21.

    Onida, S.; Lees, H.J.; Bergner, R.; Shalhoub, J.; Holmes, E.; Davies, A.H. 1H Nuclear Magnetic Resonance Spectroscopy Reveals Changes in Metabolic Phenotype Associated with Disease Stage in Patients with Chronic Venous Disease. Eur. J. Vasc. Endovasc. Surg. 2025, 69, 325–333. https://doi.org/10.1016/j.ejvs.2024.09.019.

  • 22.

    Oliveira, N.; Sousa, A.; Amaral, A.P.; Conde, R.; Verde, I. Identification of Urine Metabolic Markers of Stroke Risk Using Untargeted Nuclear Magnetic Resonance Analysis. Int. J. Mol. Sci. 2024, 25, 7436. https://doi.org/10.3390/ijms25137436.

  • 23.

    Petersson, J.N.; Bykowski, E.A.; Ekstrand, C.; Dukelow, S.P.; Ho, C.; Debert, C.T.; Montina, T.; Metz, G.A.S. Unraveling Metabolic Changes following Stroke: Insights from a Urinary Metabolomics Analysis. Metabolites 2024, 14, 145. https://doi.org/10.3390/metabo14030145.

  • 24.

    Aldars-García, L.; Gil-Redondo, R.; Embade, N.; Riestra, S.; Rivero, M.; Gutiérrez, A.; Rodríguez-Lago, I.; Fernández-Salazar, L.; Ceballos, D.; Manuel Benítez, J.; et al. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients. Inflamm. Bowel Dis. 2024, 30, 167–182. https://doi.org/10.1093/ibd/izad154.

  • 25.

    Spadavecchia, A.; Zoccarato, M.; Tedone, G.; Biolatti, M.; Dell’Oste, V.; Leone, A.; Cossard, A.; Sozzi, M.; Bresesti, I.; Bertino, E.; et al. 1H NMR Urinary Metabolomics Profiling of Newborns with Congenital Human Cytomegalovirus Infection: Insights into Metabolic Alterations. J. Proteome Res. 2025, 24, 2112–2120. https://doi.org/10.1021/acs.jproteome.5c00017.

  • 26.

    Yan, Y.; Chen, J.; Liang, Q.; Zheng, H.; Ye, Y.; Nan, W.; Zhang, X.; Gao, H.; Li, Y. Metabolomics profile in acute respiratory distress syndrome by nuclear magnetic resonance spectroscopy in patients with community-acquired pneumonia. Respir. Res. 2022, 23, 172. https://doi.org/10.1186/s12931-022-02075-w.

  • 27.

    Vogl, F.C.; Mehrl, S.; Heizinger, L.; Schlecht, I.; Zacharias, H.U.; Ellmann, L.; Nürnberger, N.; Gronwald, W.; Leitzmann, M.F.; Rossert, J.; et al. Evaluation of dilution and normalization strategies to correct for urinary output in HPLC-HRTOFMS metabolomics. Anal. Bioanal. Chem. 2016, 408, 8483–8493. https://doi.org/10.1007/s00216-016-9974-1.

  • 28.

    Edmands, W.M.B.; Ferrari, P.; Scalbert, A. Normalization to Specific Gravity Prior to Analysis Improves Information Recovery from High Resolution Mass Spectrometry Metabolomic Profiles of Human Urine. Anal. Chem. 2014, 86, 10925–10931. https://doi.org/10.1021/ac503190m.

  • 29.

    Rosen Vollmar, A.K.; Rattray, N.J.W.; Cai, Y.; Santos-Neto, Á.J.; Deziel, N.C.; Jukic, A.M.Z.; Johnson, C.H. Normalizing Untargeted Periconceptional Urinary Metabolomics Data: A Comparison of Approaches. Metabolites 2019, 9, 198. https://doi.org/10.3390/metabo9100198.

  • 30.

    Chetwynd, A.J.; Abdul-Sada, A.; Holt, S.G.; Hill, E.M. Use of a pre-analysis osmolality normalisation method to correct for variable urine concentrations and for improved metabolomic analyses. J. Chromatogr. A 2016, 1431, 103–110. https://doi.org/10.1016/j.chroma.2015.12.056.

  • 31.

    Tang, K.W.; Toh, Q.C.; Teo, B.W. Normalisation of urinary biomarkers to creatinine for clinical practice and research—When and why. Singap. Med. J. 2015, 56, 7–10. https://doi.org/10.11622/smedj.2015003.

  • 32.

    Dieterle, F.; Ross, A.; Schlotterbeck, G.; Senn, H. Probabilistic Quotient Normalization as Robust Method to Account for Dilution of Complex Biological Mixtures. Application in 1H NMR Metabonomics. Anal. Chem. 2006, 78, 4281–4290. https://doi.org/10.1021/ac051632c.

  • 33.

    Zomorodian, A.; Moe, O.W. Citrate and calcium kidney stones. Clin. Kidney J. 2025, 18, sfaf244. https://doi.org/10.1093/ckj/sfaf244.

  • 34.

    Dekker, S.E.I.; Verhoeven, A.; Soonawala, D.; Peters, D.J.M.; de Fijter, J.W.; Mayboroda, O.A.; DIPAK Consortium. Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. PLoS ONE 2020, 15, e0233213. https://doi.org/10.1371/journal.pone.0233213.

  • 35.

    Zacchia, M.; Tian, X.; Zona, E.; Alpern, R.J.; Preisig, P.A. Acid Stimulation of the Citrate Transporter NaDC-1 Requires Pyk2 and ERK1/2 Signaling Pathways. J. Am. Soc. Nephrol. 2018, 29, 1720–1730. https://doi.org/10.1681/asn.2017121268.

  • 36.

    Hering-Smith, K.S.; Gambala, C.T.; Hamm, L.L. Citrate and succinate transport in proximal tubule cells. Am. J. Physiol.-Ren. Physiol. 2000, 278, F492–F498. https://doi.org/10.1152/ajprenal.2000.278.3.F492.

  • 37.

    Gianella, F.G.; Prado, V.E.; Poindexter, J.R.; Adams-Huet, B.; Li, X.; Miller, R.T.; Sakhaee, K.; Maalouf, N.M.; Moe, O.W. Spot urinary citrate-to-creatinine ratio is a marker for acid-base status in chronic kidney disease. Kidney Int. 2021, 99, 208–217. https://doi.org/10.1016/j.kint.2020.07.006.

  • 38.

    Gronwald, W.; Klein, M.S.; Zeltner, R.; Schulze, B.-D.; Reinhold, S.W.; Deutschmann, M.; Immervoll, A.-K.; Böger, C.A.; Banas, B.; Eckardt, K.-U.; et al. Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int. 2011, 79, 1244–1253. https://doi.org/10.1038/ki.2011.30.

  • 39.

    Rist, M.; Muhle-Goll, C.; Görling, B.; Bub, A.; Heissler, S.; Watzl, B.; Luy, B. Influence of Freezing and Storage Procedure on Human Urine Samples in NMR-Based Metabolomics. Metabolites 2013, 3, 243–258. https://doi.org/10.3390/metabo3020243.

  • 40.

    Gupta, A.; Kashyap, S.; Meena, K.; Kumar, D.; Gaurav, A.; Sahu, A.K.; Yadav, S.; Kumar, S.; Kapoor, A. NMR-based metabolic measures of chronic stable angina and myocardial infarction in patients with diabetes mellitus. Clin. Chim. Acta 2026, 585, 120883. https://doi.org/10.1016/j.cca.2026.120883.

  • 41.

    Gil-Redondo, R.; Conde, R.; Bruzzone, C.; Seco, M.L.; Bizkarguenaga, M.; González-Valle, B.; de Diego, A.; Laín, A.; Habisch, H.; Haudum, C.; et al. MetSCORE: A molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics. Cardiovasc. Diabetol. 2024, 23, 272. https://doi.org/10.1186/s12933-024-02363-3.

  • 42.

    Qin, J.; Ling, X.; Wang, Q.; Huang, Z.; Guo, B.; Zhang, C.; Meng, M.; Feng, S.; Guo, Y.; Zheng, H.; et al. Integrated Gut Microbiota and Urine Metabolite Analyses of T2DM with NAFLD Rat Model. Appl. Biochem. Biotechnol. 2023, 195, 6478–6494. https://doi.org/10.1007/s12010-023-04419-8.

  • 43.

    Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; DuGar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.-M.; et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57–63. https://doi.org/10.1038/nature09922.

  • 44.

    Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-Gut Microbiota Metabolic Interactions. Science 2012, 336, 1262–1267. https://doi.org/10.1126/science.1223813.

  • 45.

    Xie, R.; Herder, C.; Sha, S.; Peng, L.; Brenner, H.; Schöttker, B. Novel type 2 diabetes prediction score based on traditional risk factors and circulating metabolites: Model derivation and validation in two large cohort studies. eClinicalMedicine 2025, 79, 102971. https://doi.org/10.1016/j.eclinm.2024.102971.

  • 46.

    Edgar, M.; Percival, B.C.; Gibson, M.; Jafari, F.; Grootveld, M. Low-field benchtop NMR spectroscopy as a potential non-stationary tool for point-of-care urinary metabolite tracking in diabetic conditions. Diabetes Res. Clin. Pract. 2021, 171, 108554. https://doi.org/10.1016/j.diabres.2020.108554.

  • 47.

    Yu, J.; Ren, J.; Ren, Y.; Wu, Y.; Zeng, Y.; Zhang, Q.; Xiao, X. Using metabolomics and proteomics to identify the potential urine biomarkers for prediction and diagnosis of gestational diabetes. eBioMedicine 2024, 101, 105008. https://doi.org/10.1016/j.ebiom.2024.105008.

  • 48.

    Percival, B.C.; Grootveld, M.; Gibson, M.; Osman, Y.; Molinari, M.; Jafari, F.; Sahota, T.; Martin, M.; Casanova, F.; Mather, M.L.; et al. Low-Field, Benchtop NMR Spectroscopy as a Potential Tool for Point-of-Care Diagnostics of Metabolic Conditions: Validation, Protocols and Computational Models. High-Throughput 2018, 8, 2. https://doi.org/10.3390/ht8010002.

  • 49.

    Wu, Q.; Huang, Q.-X.; Zeng, H.-L.; Ma, S.; Lin, H.-D.; Xia, M.-F.; Tang, H.-R.; Gao, X. Prediction of Metabolic Disorders Using NMR-Based Metabolomics: The Shanghai Changfeng Study. Phenomics 2021, 1, 186–198. https://doi.org/10.1007/s43657-021-00021-2.

  • 50.

    Pujos-Guillot, E.; Brandolini, M.; Pétéra, M.; Grissa, D.; Joly, C.; Lyan, B.; Herquelot, É.; Czernichow, S.; Zins, M.; Goldberg, M.; et al. Systems Metabolomics for Prediction of Metabolic Syndrome. J. Proteome Res. 2017, 16, 2262–2272. https://doi.org/10.1021/acs.jproteome.7b00116.

  • 51.

    Zhao, M.; Li, R.; Miao, C.; Miccoli, P.; Lu, J. Non-invasive diagnosis of papillary thyroid microcarcinoma using a novel metabolomics analysis of urine. Endocrine 2024, 87, 1100–1111. https://doi.org/10.1007/s12020-024-04105-7.

  • 52.

    Jiménez, B.; Abellona U, M.R.; Drymousis, P.; Kyriakides, M.; Clift, A.K.; Liu, D.S.K.; Rees, E.; Holmes, E.; Nicholson, J.K.; Kinross, J.M.; et al. Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility. Cancers 2021, 13, 374. https://doi.org/10.3390/cancers13030374.

  • 53.

    Sahni, S.; Pandya, A.R.; Hadden, W.J.; Nahm, C.B.; Maloney, S.; Cook, V.; Toft, J.A.; Wilkinson-White, L.; Gill, A.J.; Samra, J.S.; et al. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Int. J. Cancer 2020, 148, 1508–1518. https://doi.org/10.1002/ijc.33368.

  • 54.

    Ahmed, N.; Kidane, B.; Wang, L.; Nugent, Z.; Moldovan, N.; McElrea, A.; Shariati-Ievari, S.; Qing, G.; Tan, L.; Buduhan, G.; et al. Metabolic Changes in Early-Stage Non–Small Cell Lung Cancer Patients after Surgical Resection. Cancers 2021, 13, 3012. https://doi.org/10.3390/cancers13123012.

  • 55.

    Gellrich, F.F.; Hufnagel, C.; Funk, A.M.; Jonas, S.; Altmann, H.; Hobelsberger, S.; Steininger, J.; Feige, C.; Tasdogan, A.; Chavakis, T.; et al. 1H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis. Sci. Rep. 2026, 16, 5263. https://doi.org/10.1038/s41598-026-37118-5.

  • 56.

    Ferreira, M.R.; Sands, C.J.; Li, J.V.; Andreyev, J.N.; Chekmeneva, E.; Gulliford, S.; Marchesi, J.; Lewis, M.R.; Dearnaley, D.P. Impact of Pelvic Radiation Therapy for Prostate Cancer on Global Metabolic Profiles and Microbiota-Driven Gastrointestinal Late Side Effects: A Longitudinal Observational Study. Int. J. Radiat. Oncol. Biol. Phys. 2021, 111, 1204–1213. https://doi.org/10.1016/j.ijrobp.2021.07.1713.

  • 57.

    Oliveira, M.S.; Santo, R.C.E.; Silva, J.M.S.; Alabarse, P.V.G.; Brenol, C.V.; Young, S.P.; Xavier, R.M. Urinary metabolomic biomarker candidates for skeletal muscle wasting in patients with rheumatoid arthritis. J. Cachexia Sarcopenia Muscle 2023, 14, 1657–1669. https://doi.org/10.1002/jcsm.13240.

  • 58.

    Jutley, G.S.; Sahota, K.; Sahbudin, I.; Filer, A.; Arayssi, T.; Young, S.P.; Raza, K. Relationship Between Inflammation and Metabolism in Patients With Newly Presenting Rheumatoid Arthritis. Front. Immunol. 2021, 12, 676105. https://doi.org/10.3389/fimmu.2021.676105.

  • 59.

    Rosolanka, R.; Liptak, P.; Baranovicova, E.; Bobcakova, A.; Vysehradsky, R.; Duricek, M.; Kapinova, A.; Dvorska, D.; Dankova, Z.; Simekova, K.; et al. Changes in the Urine Metabolomic Profile in Patients Recovering from Severe COVID-19. Metabolites 2023, 13, 364. https://doi.org/10.3390/metabo13030364.

  • 60.

    Marhuenda-Egea, F.C.; Narro-Serrano, J.; Shalabi-Benavent, M.J.; Álamo-Marzo, J.M.; Amador-Prous, C.; Algado-Rabasa, J.T.; Garijo-Saiz, A.M.; Marco-Escoto, M. A metabolic readout of the urine metabolome of COVID-19 patients. Metabolomics 2023, 19, 7. https://doi.org/10.1007/s11306-023-01971-6.

  • 61.

    Tristán, A.I.; Jiménez-Luna, C.; Abreu, A.C.; Arrabal-Campos, F.M.; Salmerón, A.d.M.; Rodríguez, F.I.; Maresca, M.Á.R.; García, A.B.; Melguizo, C.; Prados, J.; et al. Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts. Sci. Rep. 2024, 14, 23713. https://doi.org/10.1038/s41598-024-74641-9.

  • 62.

    Stephens, N.S.; Siffledeen, J.; Su, X.; Murdoch, T.B.; Fedorak, R.N.; Slupsky, C.M. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J. Crohn’s Colitis 2013, 7, e42–e48. https://doi.org/10.1016/j.crohns.2012.04.019.

  • 63.

    Embade, N.; Cannet, C.; Diercks, T.; Gil-Redondo, R.; Bruzzone, C.; Ansó, S.; Echevarría, L.R.; Ayucar, M.M.M.; Collazos, L.; Lodoso, B.; et al. NMR-based newborn urine screening for optimized detection of inherited errors of metabolism. Sci. Rep. 2019, 9, 13067. https://doi.org/10.1038/s41598-019-49685-x.

  • 64.

    Ismail, I.T.; Showalter, M.R.; Fiehn, O. Inborn Errors of Metabolism in the Era of Untargeted Metabolomics and Lipidomics. Metabolites 2019, 9, 242. https://doi.org/10.3390/metabo9100242.

  • 65.

    Scalabre, A.; Clément, Y.; Guillière, F.; Ayciriex, S.; Gaillard, S.; Demède, D.; Bouty, A.; Lanteri, P.; Mure, P.-Y. Early detection of ureteropelvic junction obstruction in neonates with prenatal diagnosis of renal pelvis dilatation using 1H NMR urinary metabolomics. Sci. Rep. 2022, 12, 13406. https://doi.org/10.1038/s41598-022-17664-4.

  • 66.

    Saffari, A.; Niesert, M.; Cannet, C.; Blaschek, A.; Hahn, A.; Johannsen, J.; Kockaya, M.; Kölbel, H.; Hoffmann, G.F.; Claus, P.; et al. Identification of Biochemical Determinants for Diagnosis and Prediction of Severity in 5q Spinal Muscular Atrophy Using 1H-Nuclear Magnetic Resonance Metabolic Profiling in Patient-Derived Biofluids. Int. J. Mol. Sci. 2024, 25, 12123. https://doi.org/10.3390/ijms252212123.

  • 67.

    Swann, J.R.; Diaz Heijtz, R.; Mayneris-Perxachs, J.; Arora, A.; Isaksson, J.; Bölte, S.; Tammimies, K. Characterizing the metabolomic signature of attention-deficit hyperactivity disorder in twins. Neuropharmacology 2023, 234, 109562. https://doi.org/10.1016/j.neuropharm.2023.109562.

  • 68.

    Sotelo-Orozco, J.; Schmidt, R.J.; Slupsky, C.M.; Hertz-Picciotto, I. Investigating the Urinary Metabolome in the First Year of Life and Its Association with Later Diagnosis of Autism Spectrum Disorder or Non-Typical Neurodevelopment in the MARBLES Study. Int. J. Mol. Sci. 2023, 24, 9454. https://doi.org/10.3390/ijms24119454.

  • 69.

    Yap, I.K.S.; Angley, M.; Veselkov, K.A.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. Urinary Metabolic Phenotyping Differentiates Children with Autism from Their Unaffected Siblings and Age-Matched Controls. J. Proteome Res. 2010, 9, 2996–3004. https://doi.org/10.1021/pr901188e.

  • 70.

    Mavel, S.; Nadal-Desbarats, L.; Blasco, H.; Bonnet-Brilhault, F.; Barthélémy, C.; Montigny, F.; Sarda, P.; Laumonnier, F.; Vourc′h, P.; Andres, C.R.; et al. 1H–13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta 2013, 114, 95–102. https://doi.org/10.1016/j.talanta.2013.03.064.

  • 71.

    Marino, C.; Zhang, S.; De Simone, G.; Grimaldi, M.; Di Maio, A.; Iasevoli, F.; Errico, F.; D’Ursi, A.M.; de Bartolomeis, A.; Usiello, A. Untargeted 1H NMR-based metabolomics unveils distinct circulating biochemical signatures between treatment-resistant and non-treatment-resistant schizophrenia patients: A pilot study. Transl. Psychiatry 2026, 16, 108. https://doi.org/10.1038/s41398-026-03853-6.

  • 72.

    Papadopoulou, E.; Siskos, A.P.; Stratakis, N.; Nguyen, A.N.; Zhao, Y.; Margetaki, K.; Lau, C.-H.E.; Coen, M.; Maitre, L.; Fernández-Barrés, S.; et al. Urinary metabolic biomarkers of diet quality in European children are associated with metabolic health. eLife 2022, 11, e71332. https://doi.org/10.7554/eLife.71332.

  • 73.

    Oude Griep, L.M.; Chekmeneva, E.; Van Horn, L.; Chan, Q.; Daviglus, M.L.; Frost, G.; Holmes, E.; Ebbels, T.M.D.; Elliott, P. A Metabolome Wide Association Study of Fruit and Vegetable Consumption and Associations with Cardiovascular Disease Risk Factors: The International Study of Macro-/Micronutrients and Blood Pressure (INTERMAP) Study. J. Nutr. 2025, 155, 122–131. https://doi.org/10.1016/j.tjnut.2024.11.004.

  • 74.

    Clarke, E.D.; Gómez-Martín, M.; Stanford, J.; Yilmaz, A.; Ustun, I.; Wood, L.; Green, B.; Graham, S.F.; Collins, C.E. Urinary Metabolite Profiles of Participants with Overweight and Obesity Prescribed a Weight Loss High Fruit and Vegetable Diet: A Single Arm Intervention Study. Nutrients 2024, 16, 4358. https://doi.org/10.3390/nu16244358.

  • 75.

    Correia, B.S.B.; Dalgaard, L.B.; Thams, L.; Hansen, M.; Bertram, H.C. Changes in the urinary metabolome accompanied alterations in body mass and composition in women with overweight—Impact of high versus low protein breakfast. Metabolomics 2024, 20, 81. https://doi.org/10.1007/s11306-024-02156-5.

  • 76.

    Zheng, C.; Gowda, G.A.N.; Raftery, D.; Neuhouser, M.L.; Tinker, L.F.; Prentice, R.L.; Beresford, S.A.A.; Zhang, Y.; Bettcher, L.; Pepin, R.; et al. Evaluation of potential metabolomic-based biomarkers of protein, carbohydrate and fat intakes using a controlled feeding study. Eur. J. Nutr. 2021, 60, 4207–4218. https://doi.org/10.1007/s00394-021-02577-1.

  • 77.

    Rowley, C.E.; Lodge, S.; Egan, S.; Itsiopoulos, C.; Christophersen, C.T.; Silva, D.; Kicic-Starcevich, E.; O’Sullivan, T.A.; Wist, J.; Nicholson, J.; et al. Altered dietary behaviour during pregnancy impacts systemic metabolic phenotypes. Front. Nutr. 2023, 10, 1230480. https://doi.org/10.3389/fnut.2023.1230480.

  • 78.

    Brial, F.; Chilloux, J.; Nielsen, T.; Vieira-Silva, S.; Falony, G.; Andrikopoulos, P.; Olanipekun, M.; Hoyles, L.; Djouadi, F.; Neves, A.L.; et al. Human and preclinical studies of the host–gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health. Gut 2021, 70, 2105–2114. https://doi.org/10.1136/gutjnl-2020-323314.

  • 79.

    He, X.; Tinghäll Nilsson, U.; Mishchuk, D.O.; Hernell, O.; Lönnerdal, B.; Hartvigsen, M.L.; Jacobsen, L.N.; Kvistgaard, A.S.; Slupsky, C.M.; Karlsland Åkeson, P. Impact of formula protein quantity and source on infant metabolism: Serum, urine, and fecal metabolomes of a randomized controlled study. Am. J. Clin. Nutr. 2025, 121, 853–864. https://doi.org/10.1016/j.ajcnut.2025.02.002.

  • 80.

    Falaina, V.; Fotakis, C.; Boutsikou, T.; Tsiaka, T.; Moros, G.; Ouzounis, S.; Andreou, V.; Iliodromiti, Z.; Xanthos, T.; Vandenplas, Y.; et al. Urine Metabolomic Profile of Breast- versus Formula-Fed Neonates Using a Synbiotic-Enriched Formula. Int. J. Mol. Sci. 2022, 23, 10476. https://doi.org/10.3390/ijms231810476.

  • 81.

    Kistner, S.; Mack, C.I.; Rist, M.J.; Krüger, R.; Egert, B.; Biniaminov, N.; Engelbert, A.K.; Seifert, S.; Dörr, C.; Ferrario, P.G.; et al. Acute effects of moderate vs. vigorous endurance exercise on urinary metabolites in healthy, young, physically active men—A multi-platform metabolomics approach. Front. Physiol. 2023, 14, 1028643. https://doi.org/10.3389/fphys.2023.1028643.

  • 82.

    West, K.A.; Kanu, C.; Maric, T.; McDonald, J.A.K.; Nicholson, J.K.; Li, J.V.; Johnson, M.R.; Holmes, E.; Savvidou, M.D. Longitudinal metabolic and gut bacterial profiling of pregnant women with previous bariatric surgery. Gut 2020, 69, 1452–1459. https://doi.org/10.1136/gutjnl-2019-319620.

  • 83.

    Sanchez-Rodriguez, L.; Galvez-Fernandez, M.; Rojas-Benedicto, A.; Domingo-Relloso, A.; Amigo, N.; Redon, J.; Monleon, D.; Saez, G.; Tellez-Plaza, M.; Martin-Escudero, J.C.; et al. Traffic Density Exposure, Oxidative Stress Biomarkers and Plasma Metabolomics in a Population-Based Sample: The Hortega Study. Antioxidants 2023, 12, 2122. https://doi.org/10.3390/antiox12122122.

  • 84.

    Enea, C.; Seguin, F.; Petitpas-Mulliez, J.; Boildieu, N.; Boisseau, N.; Delpech, N.; Diaz, V.; Eugène, M.; Dugué, B. 1H NMR-based metabolomics approach for exploring urinary metabolome modifications after acute and chronic physical exercise. Anal. Bioanal. Chem. 2009, 396, 1167–1176. https://doi.org/10.1007/s00216-009-3289-4.

  • 85.

    Favé, G.; Beckmann, M.; Lloyd, A.J.; Zhou, S.; Harold, G.; Lin, W.; Tailliart, K.; Xie, L.; Draper, J.; Mathers, J.C. Development and validation of a standardized protocol to monitor human dietary exposure by metabolite fingerprinting of urine samples. Metabolomics 2011, 7, 469–484. https://doi.org/10.1007/s11306-011-0289-0.

  • 86.

    Wallner-Liebmann, S.; Gralka, E.; Tenori, L.; Konrad, M.; Hofmann, P.; Dieber-Rotheneder, M.; Turano, P.; Luchinat, C.; Zatloukal, K. The impact of free or standardized lifestyle and urine sampling protocol on metabolome recognition accuracy. Genes Nutr. 2014, 10, 441. https://doi.org/10.1007/s12263-014-0441-3.

  • 87.

    Brennan, L.; Kim, K.; Mall, C.; Taylor, S.L.; Hitchcock, S.; Zhang, C.; Wettersten, H.I.; Jones, A.D.; Chapman, A.; Weiss, R.H. Mealtime, Temporal, and Daily Variability of the Human Urinary and Plasma Metabolomes in a Tightly Controlled Environment. PLoS ONE 2014, 9, e86223. https://doi.org/10.1371/journal.pone.0086223.

  • 88.

    Lindqvist, H.M.; Rådjursöga, M.; Torstensson, T.; Jansson, L.; Ellegård, L.; Winkvist, A. Urine Metabolite Profiles and Nutrient Intake Based on 4-Day Weighed Food Diary in Habitual Vegans, Vegetarians, and Omnivores. J. Nutr. 2021, 151, 30–39. https://doi.org/10.1093/jn/nxaa019.

  • 89.

    Lee, K.S.; Su, X.; Huan, T. Metabolites are not genes—avoiding the misuse of pathway analysis in metabolomics. Nat. Metab. 2025, 7, 858–861. https://doi.org/10.1038/s42255-025-01283-0.

  • 90.

    Pallister, T.; Jackson, M.A.; Martin, T.C.; Zierer, J.; Jennings, A.; Mohney, R.P.; MacGregor, A.; Steves, C.J.; Cassidy, A.; Spector, T.D.; et al. Hippurate as a metabolomic marker of gut microbiome diversity: Modulation by diet and relationship to metabolic syndrome. Sci. Rep. 2017, 7, 13670. https://doi.org/10.1038/s41598-017-13722-4.

  • 91.

    Lees, H.J.; Swann, J.R.; Wilson, I.D.; Nicholson, J.K.; Holmes, E. Hippurate: The Natural History of a Mammalian–Microbial Cometabolite. J. Proteome Res. 2013, 12, 1527–1546. https://doi.org/10.1021/pr300900b.

  • 92.

    Salek, R.M.; Steinbeck, C.; Viant, M.R.; Goodacre, R.; Dunn, W.B. The role of reporting standards for metabolite annotation and identification in metabolomic studies. GigaScience 2013, 2, 13. https://doi.org/10.1186/2047-217x-2-13.

  • 93.

    Dey, A.; Charrier, B.; Martineau, E.; Deborde, C.; Gandriau, E.; Moing, A.; Jacob, D.; Eshchenko, D.; Schnell, M.; Melzi, R.; et al. Hyperpolarized NMR Metabolomics at Natural 13C Abundance. Anal. Chem. 2020, 92, 14867–14871. https://doi.org/10.1021/acs.analchem.0c03510.

  • 94.

    Lichtenberg, S.; Trifonova, O.P.; Maslov, D.L.; Balashova, E.E.; Lokhov, P.G. Metabolomic Laboratory-Developed Tests: Current Status and Perspectives. Metabolites 2021, 11, 423. https://doi.org/10.3390/metabo11070423.

  • 95.

    van der Pol, S.; Rojas Garcia, P.; Antoñanzas Villar, F.; Postma, M.J.; van Asselt, A.D.I. Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting. PharmacoEconomics 2021, 39, 1355–1363. https://doi.org/10.1007/s40273-021-01104-8.

  • 96.

    Tolstikov, V.; Akmaev, V.R.; Sarangarajan, R.; Narain, N.R.; Kiebish, M.A. Clinical metabolomics: A pivotal tool for companion diagnostic development and precision medicine. Expert Rev. Mol. Diagn. 2017, 17, 411–413. https://doi.org/10.1080/14737159.2017.1308827.

Share this article:
Download PDF
DOI
10.53941/hm.2026.100017
Issue
Volume 3, Issue 3
How to Cite
Yang, Q.; Zhou, Z.; Lin, Y.-H. Advances in Clinical Applications of 1H NMR-Based Urine Metabolomics. Health and Metabolism 2026, 3 (3), 10. https://doi.org/10.53941/hm.2026.100017.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.